Navigation Links
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
Date:6/5/2008

bout MPS IVA

Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disease characterized by deficient activity of N-acetylgalactosamine-6- sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. Malformation of the thorax impairs respiratory function, and odontoid hypoplasia and ligamentous laxity cause cervical spinal instability and potentially cord compression. Other symptoms may include hearing loss, corneal clouding, and heart valvular disease. Initial symptoms often become evident in the first five years of life. Depending on severity of the disease, age of diagnosis will vary.

The rate of incidence of MPS IVA is as yet unconfirmed, but estimates vary between 1 in 200,000 live births to 1 in 300,000 live births. Approximately 370 patients worldwide are currently registered in The International Morquio Organization (IMO) survey. An estimated 1,100 patients in the developed world have MPS VI and an estimated 3,000 patients in the developed world have MPS I.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular in
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Host Research and Development Day June 5th
2. BioMarin to Present at the Bank of America Healthcare Conference
3. BioMarin Announces First Quarter 2008 Financial Results
4. BioMarin to Present at the Morgan Stanley Healthcare Conference
5. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
6. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
9. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
10. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
11. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... law H.R. 83, the Omnibus and Continuing Resolution Appropriations ... hydrocephalus a condition eligible to receive funding through the ... Department of Defense (DoD). The Hydrocephalus Association (HA), working ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for Reproductive Medicine ... research in reproductive medicine. In his new role as ... board and will have a voice in furthering the mission ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... , Revamilast is a PDE4 inhibitor, under ... The molecule successfully completed pre-clinical trials and Phase I studies ... in the UK , , Glenmark has initiated global ... Huge unmet medical need as globally they are over 300 ...
... 9, 2011 Accuray Incorporated (Nasdaq: ARAY ), ... is scheduled to present at the Wedbush Life Sciences: Management ... at 9:10 a.m. ET/6:10 a.m. PT. A live ... investor relations page of the Company,s Web site at ...
... 2011 Reportlinker.com announces that a new ... catalogue: Biochips: Genosensors, Microarrays, ... http://www.reportlinker.com/p0591346/ Biochips-Genosensors-Microarrays-Labs-On-The-Chip .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Microarrays and Labs-on-the-Chip are extensions of biosensor ...
Cached Biology Technology:Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 2Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 3Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 4Biochips: Genosensors, Microarrays, Labs-On-The-Chip 2
(Date:12/24/2014)... launch in December 2014, the 1U™ app has ... to remember their usernames and passwords through replacing the antiquated ... assist people who have struggled to remember usernames and passwords, ... focuses on redefining identity, announced today that it is offering ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced the ... Security Systems Market" report to their offering. ... perimeter security market is estimated to grow at a CAGR ... holds a larger share in this market, Canada ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced today ... to confirm its adherence to current U.S. Food and ... conduct regulated smart device and smart phone application trials ... quality. "HITLAB is determined to improve global ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... this week,s issue of "New Scientist" magazine, research by Rice ... is on one,s mind about politics may be influenced by ... this topic for a number of years, and his team ... in the United States and supplemented it with findings from ...
... Quest Product Development, teaming with,Ball Aerospace & ... successfully demonstrated a new thermal insulation. NASA has ... II grant to develop and,commercialize this advanced thermal ... NASA,s new,spacecraft and exploration missions would preserve rocket ...
... Rochet, a research scientist at IFREMER (The French Research ... the prestigious Pew Fellowship in Marine Conservation to determine ... to the delicately balanced marine ecosystem. She will use ... use of that technique, and to further improve its ...
Cached Biology News:Colorado Engineering Firms Win NASA Grant to Develop Innovative Insulation for Next Generation Spacecraft - Super-Insulation May Allow Future Energy Efficient Appliances 22008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 22008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 32008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 4
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
... 100-240 V, uses multiplex suspension array technology ... up to 100 proteins and peptides in ... is composed of up to 100 color-coded ... conjugated with a unique reactant specific to ...
... (HTF) system, 100-240 V, is an optional ... that automates delivery of up to 20 ... array reader. The HTF system automatically draws ... container to constantly maintain a reservoir of ...
Cell Culture Flask, 75 cm, nontreated polystyrene...
Biology Products: